DIMETHYL FUMARATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Dimethyl Fumarate, and when can generic versions of Dimethyl Fumarate launch?
Dimethyl Fumarate is a drug marketed by Accord Hlthcare, Alkem Labs Ltd, Amneal, Aurobindo Pharma, Cipla, Glenmark Pharms Ltd, Hetero Labs Ltd Iii, Lupin, Macleods Pharms Ltd, MSN, Mylan, Prinston Inc, Sawai Usa, Sola Pharms, Twi Pharms, and Zydus Pharms. and is included in sixteen NDAs.
The generic ingredient in DIMETHYL FUMARATE is dimethyl fumarate. There are seventy-six drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the dimethyl fumarate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Dimethyl Fumarate
A generic version of DIMETHYL FUMARATE was approved as dimethyl fumarate by MYLAN on August 17th, 2020.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DIMETHYL FUMARATE?
- What are the global sales for DIMETHYL FUMARATE?
- What is Average Wholesale Price for DIMETHYL FUMARATE?
Summary for DIMETHYL FUMARATE
| US Patents: | 0 |
| Applicants: | 16 |
| NDAs: | 16 |
| Finished Product Suppliers / Packagers: | 19 |
| Raw Ingredient (Bulk) Api Vendors: | 129 |
| Clinical Trials: | 71 |
| Drug Prices: | Drug price information for DIMETHYL FUMARATE |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for DIMETHYL FUMARATE |
| What excipients (inactive ingredients) are in DIMETHYL FUMARATE? | DIMETHYL FUMARATE excipients list |
| DailyMed Link: | DIMETHYL FUMARATE at DailyMed |
Recent Clinical Trials for DIMETHYL FUMARATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Imcyse SA | Phase 1/Phase 2 |
| Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Xuanwu Hospital, Beijing | Phase 2 |
Medical Subject Heading (MeSH) Categories for DIMETHYL FUMARATE
Anatomical Therapeutic Chemical (ATC) Classes for DIMETHYL FUMARATE
Paragraph IV (Patent) Challenges for DIMETHYL FUMARATE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| TECFIDERA | Delayed-release Capsules | dimethyl fumarate | 120 mg and 240 mg | 204063 | 29 | 2017-03-27 |
US Patents and Regulatory Information for DIMETHYL FUMARATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zydus Pharms | DIMETHYL FUMARATE | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 210538-002 | Sep 24, 2020 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sola Pharms | DIMETHYL FUMARATE | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 210436-002 | Mar 26, 2021 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Twi Pharms | DIMETHYL FUMARATE | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 210382-001 | Oct 14, 2020 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for DIMETHYL FUMARATE
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Almirall S.A | Skilarence | dimethyl fumarate | EMEA/H/C/002157 Skilarence is indicated for the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy. |
Authorised | no | no | no | 2017-06-23 | |
| Biogen Netherlands B.V. | Tecfidera | dimethyl fumarate | EMEA/H/C/002601 Tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS). |
Authorised | no | no | no | 2014-01-30 | |
| Mylan Ireland Limited | Dimethyl fumarate Mylan | dimethyl fumarate | EMEA/H/C/005956 Dimethyl fumarate Mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis. |
Authorised | yes | no | no | 2022-05-13 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
